Last reviewed · How we verify
FOLFIRINOX or gemcitabine-nab-paclitaxel
FOLFIRINOX and gemcitabine-nab-paclitaxel are combination chemotherapy regimens that kill rapidly dividing cancer cells through multiple mechanisms of DNA damage and microtubule disruption.
FOLFIRINOX and gemcitabine-nab-paclitaxel are combination chemotherapy regimens that kill rapidly dividing cancer cells through multiple mechanisms of DNA damage and microtubule disruption. Used for Metastatic pancreatic cancer (FOLFIRINOX), Metastatic pancreatic cancer (gemcitabine-nab-paclitaxel), Locally advanced pancreatic cancer.
At a glance
| Generic name | FOLFIRINOX or gemcitabine-nab-paclitaxel |
|---|---|
| Sponsor | Sahlgrenska University Hospital |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFIRINOX combines 5-fluorouracil (DNA synthesis inhibitor), leucovorin (5-FU potentiator), irinotecan (topoisomerase I inhibitor), and oxaliplatin (platinum alkylating agent) to attack cancer cells via complementary pathways. Gemcitabine-nab-paclitaxel combines gemcitabine (nucleoside analog inhibiting DNA synthesis) with nab-paclitaxel (albumin-bound paclitaxel that stabilizes microtubules), allowing higher drug delivery to tumors.
Approved indications
- Metastatic pancreatic cancer (FOLFIRINOX)
- Metastatic pancreatic cancer (gemcitabine-nab-paclitaxel)
- Locally advanced pancreatic cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Fatigue
- Mucositis
Key clinical trials
- Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors (NA)
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
- Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC) (NA)
- A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) (PHASE1)
- LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study (PHASE1, PHASE2)
- NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (PHASE2)
- A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab (PHASE1, PHASE2)
- Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: